Fischer Medical Ventures profitability ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026
Returns
8.1%8.1%
4.6%4.6%
9.7%9.7%
7.1%6.0%
Margins
13.6%14.0%
13.0%13.0%
12.0%15.1%
8.1%10.1%
−33.2%−33.2%
Additional
32.2%32.9%
—0.9%
8.1%8.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FISCHER₹26.66

Fischer Medical Ventures Limited

· Pharma & Health
₹ CrorePeersTARSONSLAXMIDENTLFABTECHGKBMcap ₹1,745 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity8.078.07
Return on Assets4.624.62
Return on Capital Employed9.719.71
Return on Invested Capital6.047.07
Margins
EBITDA Margin13.9613.64
Operating Margin13.0013.00
Pretax Margin15.1012.02
Net Income Margin10.058.12
FCF Margin-33.24-33.24
Additional
Effective Tax Rate32.9432.21
Dvd Payout Ratio0.88—
Sustainable Growth Rate8.008.07
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.